Aims: The prevalence of insomnia ranges from 36% to 91% in alcohol-dependent patients and may persist after alcohol withdrawal. Acamprosate has been shown to decrease insomnia in abstinent patients. Based on a large clinical trial database, the aim of the present study is to assess the efficacy of acamprosate in reducing insomnia, and if indeed it does reduce insomnia, to better understand its action mechanism. Short Summary: The aim of the study is to confirm the efficacy of acamprosate to reduce insomnia using an individual patient data meta-analysis. Twelve studies were found including 3508 patients. After a 6-month follow-up, the mean insomnia decrease over baseline was −26% and −45% for the placebo and acamprosate groups, respectively (P < 0.001). Methods: An individual patient data meta-analysis selected all the randomized trials of acamprosate in which insomnia was documented. Our main endpoint was insomnia change after a 6-month followup, measured by the validated Short Sleep Index (SSI) derived from the Hamilton Depression and Anxiety Scale. The meta-analysis was conducted using a two-level multilevel (patient/trial) mixed model with random treatment effect, random study effect and adjusting for baseline severity covariates. Results: Twelve studies were found including 3508 patients, 59.8% of whom were suffering from insomnia (95% CI 58.1-61.4). Psychiatric history, severe addiction, living alone and abnormal gamma-GT levels were found to be the risk factors of insomnia. After 6 months, the mean SSI decrease over baseline was −26% and −45% for placebo and acamprosate, respectively (treatment effect = 19%, 12.5-25.5; P < 0.001). By using a univariate mediation model, we found that the mediating effect of abstinence on insomnia accounted for 55.7% of the overall effect of acamprosate on insomnia reduction. Conclusions: Insomnia is prevalent among alcohol-dependent patients. It decreases spontaneously with abstinence but more frequently with acamprosate treatment.
INTRODUCTION
A marked prevalence of insomnia (from 36% to 91%) has been reported in patients admitted for treatment of alcohol dependence (Brower, 2003) . Insomnia may persist after alcohol withdrawal (Brower et al., 2001) , until more than 2 years post-withdrawal (Drummond et al., 1998) . The persistence of insomnia is considered to be an important factor in alcohol relapse during follow-up of several months in abstinent patients (Drummond et al., 1998; Foster and Peters, 1999; Brower et al., 2001) . This motivated clinicians to manage insomnia and drinking problems simultaneously in order to improve the abstinence rate (Arnedt et al., 2007) . However, Brower et al. (2008) failed to demonstrate the combined efficacy of gabapentin for treatment of insomnia and prevention of relapse in alcohol-dependent patients. Moreover, trazodone, commonly prescribed for insomnia in alcoholdependent patients, has shown short-term benefit on sleep quality but might impede improvement in alcohol consumption during the postdetoxification period (Friedmann et al., 2008) .
Acamprosate is a glutamatergic inhibitor enhancing the abstinence rate in alcohol-dependent patients (Mann et al., 2004; Rösner et al., 2010; Jonas et al., 2014) . Post hoc results from a US randomized trial suggested a direct beneficial effect of acamprosate in reducing insomnia, which is only partly explained by the indirect mediating effect of the increase in abstinence rate and thus suggesting other effects of acamprosate (Perney et al., 2012) . A putative mechanism of action has been suggested through regulation of the glutamatergic axis exerting a positive impact on sleep disorders (Boeijinga et al., 2004; Staner et al., 2006) . This positive effect of acamprosate based on post hoc results needed stronger evidence, based on more trials. Unfortunately, among the multiple studies on acamprosate, insomnia was seldom reported in results. The feasibility of a meta-analytical approach based on historical trials was provided by the recent validation of the Short Sleep Index (SSI) directly derived from Hamilton Depression and Anxiety Scales (Perney et al., 2012 (Perney et al., , 2015 . As the Hamilton Depression and Anxiety Scale was used in many alcoholism trials, SSI validation provided us with a providential estimate of insomnia.
The main aim of this study is to assess the efficacy of acamprosate in reducing insomnia, based on the largest set of randomized controlled trials. The secondary aims are to assess if the hypothetical acamprosate effect exists for all alcoholic patients or is limited to well-defined subgroups and to what extent can it be explained by the mediating effect of abstinence.
MATERIALS AND METHODS

Protocol
A meta-analysis based on individual patient data was conducted. An initial protocol was set up, describing trial-searching strategy, validity assessment of studies, study selection and data file constitution in conformity with existing guidelines (PRISMA: Moher et al., 2009) .
We selected double-blind, parallel group, randomized, controlled trials. Participants were alcohol-dependent patients defined following the criteria of the Diagnostic and Statistical Manual of Mental Disorders or the International Statistical Classification of Diseases. Intervention was acamprosate used at any dosage, irrespective of treatment duration and dose. Before treatment, patients were detoxified during at least 2 or 3 days, except in one study (Mason et al., 2006) , in which about half the patients were actively drinking when treatment with acamprosate or placebo was started.
To the existing meta-analyses on acamprosate (Mann et al., 2004; Rösner et al., 2010; Mason and Lehert, 2012) , we searched for new trials by performing a literature search (language unrestricted) covering the period from January 1, 1985, to December 30, 2013, based on a keyword set (alcohol drinking, clinical trials, acamprosate, placebo-controlled). The references retrieved from CINHAL, Psych-INFO, MEDLINE, Google Scholar, Cochrane Drugs and Alcohol Group's Trials Register were manually duplicated; the references retrieved from EMBASE and the EMBASE databases were initially duplicated using the OVID duplication facility but were also manually rechecked. An additional manual search was conducted on relevant journals, symposia, conference proceedings and relevant trials retrieved.
The raw data were obtained through a lengthy investigation involving the main authors and the drug manufacturer, as follows: a pre-project determined a cross-referenced table of all available variables, and variables documented at least in 75% of the studies were included in the database. Data checks against the original CRFs were performed by a Quality Control Binomial Test. Post hoc contact was needed with the authors to discuss data reliability and possible addition of patients excluded from the first analysis. Personal contact was made with the authors of the published studies to request additional unpublished or published results. Finally, access was provided by the manufacturer of acamprosate (Merck-Serono) to the internal trial reports of all their studies.
Based on the original case report forms, we identified baseline variables: study centre, country, treatment, acamprosate dosage, age, sex, weight, BMI (kg/m 2 ), civil status, family support and health status index. Consumption (number of days/week, number of drinks/drinking days), detoxification period length, drinking behaviour (abstinent or drinking alcohol), and Clinical Global Impression scored as 0 = Mild, 1 = Moderate, 2 = Severe and 3 = very severe were assessed. Psychiatric history was reported as history of depression and/or anxiety, and score 0 (no history), 1 = Mild/moderate, 2 = episode was followed by suicide attempt or hospitalization. During the study follow-up, we documented consumption (number of drinks and frequency). The study duration varied between trials; however, baseline months 3 (M3) and M6 were common to all the studies. Gamma glutamyl transferase (GGT) was reported in all the studies, and due to non-centralized laboratory, GGT value was calculated as the ratio of GGT to Upper Limit Value. The number of abstinent days and the percentage of abstinent days over the exposure duration were estimated by the Timeline Follow Back, patient diaries or self-reports of patients at each examination and compared with gamma-GT values. The percent of abstinence days was estimated by a conservative estimate by considering worst-case outcome of early terminating patients (Mason et al., 2006) .
The methodological quality was evaluated for each selected study, following a domain-based evaluation approach (Higgins and Green, 2011) admitting separate assessments for internal and external validities. The internal validity score had the following items: treatment concealed prior to allocation, outcomes of dropouts included in intention to treat analysis, assessors blind to assignment status, participants blind to assignment status, treatment providers blind, care programmes identical and withdrawals <10% trial population. The external validity score comprised inclusion/exclusion criteria clearly defined, outcome measures clearly defined, accuracy of outcome measures adequate, timing of outcome measures appropriate and quality of allocation concealment graded. To the internal validity score and external validity score, we added a statistical validity score reported by five items: power calculation, existence of baseline comparison, correction of primary endpoints or type 1 errors, appropriate statistical technique, full paper, clarity of tables and graphical results. The checklist was independently completed by the two authors and three additional independent reviewers. Inter-rater mean values were used, and Kendall's concordance coefficient is used to assess inter-rater consistency. Standardized (0-10) internal, external and statistical sum scores (internal validity score, external validity score and statistical validity score) were calculated. Correlation between the three scores was estimated through a principal components analysis to assess the relevance of an overall score. A study was rejected from the main selection when at least one of the three methodological quality scores was <5. The risk of publication bias was assessed with the funnel plot method and statistically examined with a linear regression test determining the linear regression coefficient between log odds ratio and its standard error.
No specific sleep scale was available; however, Hamilton Depression and Anxiety Scale was used in almost all the trials, providing a measurement tool of insomnia through the validated Short Sleep Index (SSI), entirely based on Hamilton Depression and Anxiety Scale (Perney et al., 2012 (Perney et al., , 2015 . In summary, SSI is the sum score of items 3-5 of the depression scale (range 0-2), and item 6 of the anxiety scale (range 0-4); thus, SSI varies from 0 to 10. These four questions are (a) insomnia early (difficulty falling asleep), (b) insomnia middle (being restless and disturbed during the night), (c) insomnia late (waking in early hours of the morning) and (d) difficulty in falling asleep, broken sleep, unsatisfying sleep and fatigue on waking, dreams, nightmares and night terrors. It has been shown that a score of SSI ≥2 is associated with at least moderate insomnia and that severe insomnia is present when SSI ≥4.
Statistical analysis
The main endpoint was the final SSI index (SSI f ). We used an individual patient-data-specific two-level model (patient/trial, Higgins et al., 2001) , in which treatment and study were assumed to have both fixed and random components effect and adjusting for fixed baseline predictors (cfr appendix for details). The available predictors of SSI, including baseline SSI (SSI b ), age, psychiatric history, and baseline addiction severity based on Clinical Global Impression, were first tested by exploratory stepwise regression, out of treatment consideration at that stage and treatment effect was then tested by adjusting the significantly predictive covariates. We compared the adjusted values among treatment groups for each study with a random model (DerSimonian and Laird, 1986) , illustrated by forest plot. Possible responder subgroups were assessed in calculating the interaction between treatment and baseline covariates. Due to expected large sample size, differences P < 0.001 were considered significant for the main effects and P < 0.05 for interactions. The confidence intervals were calculated via bootstrap calculations.
The proportions of recovered patients or therapy responders (final SSI f ≤1) (Perney et al., 2012) were compared between treatment groups using a non-linear mixed model featuring logistic regression adjusted for baseline covariates.
Rather than multiple imputation (Hallgren et al., 2016) , missing data imputation was performed according to worst-case scenario in the event of early withdrawal both for insomnia and percent of abstinent days (Mason et al., 2006) . Any patient lost to follow-up before the end of the trial was regarded as a treatment failure, except for a reason unrelated to the disease. Sensitivity analysis was conducted based on multiple allocation, mixed model and pattern mixture strategies.
Our last objective was evaluating the extent to which the acamprosate effect is entirely mediated by its known effect on abstinence (univariate mediation model; Preacher and Hayes, 2008) .
The analysis was conducted with the stat package R (version 3.0.2), the meta-analytical individual patient data model implemented with the libraries nlme and lme4 (linear and non-linear mixed effects models) and the meta-analysis graphics (forest plot) were done with the use of the Metafor library (Viechtbauer, 2010) .
RESULTS
Study and sample description
The study selection is summarized in the flow diagram (Fig. 1) . Out of 24 identified double-blind, randomized, controlled trials (n = 6543) comparing acamprosate with placebo, 12 studies reported the Hamilton Depression and Anxiety Scale, both in baseline and during follow-up (n = 3508) (Pelc et al., 1992 (Pelc et al., , 1997 Ladewig et al., 1993; Whitworth et al., 1996; Barrias et al., 1997; Geerlings et al., 1997;  Poltdrugo, 1997; Besson et al., 1998; Chick et al., 2000; Tempesta et al., 2000; Gual and Lehert, 2001; Mason et al., 2006) (Table 1 ). All these studies were eligible and none was rejected for methodological flaws. For some other studies, anxiety and depression were either not reported or measured by other scales (Covi, MADRS) not permitting insomnia measurement. Two studies compared different dose regimens of acamprosate with placebo (Pelc et al., 1997; Mason et al., 2006) . Sample sizes varied from 61 (Ladewig et al., 1993) to 590 patients (Mason et al., 2006) , most of them conducted in Europe. Treatment durations were 6 and 12 months. Daily dosage of 1.3 g or 2 g was given according to body weight lower or higher than 60 kg, respectively. In some studies, psycho-social support was provided and patients were encouraged to participate in self-help groups. All the studies were conducted blind to treatment, patients were randomized according to a centralized list and treatment identity remained concealed throughout the duration of treatment.
As only a subset of the acamprosate studies provided insomnia data, we compared our sample (n = 3058) with the subset of excluded studies of the whole database (24 studies and 6543 patients). Very little differences were observed between the two subsets on baseline variables (age, gender, BMI, living conditions, baseline addiction severity Index, has a fixed job, episodic or regular drinker, baseline number of drinks per day, GGT, psychological history, family alcohol history, anxiety history and suicide attempt history). Similarly, we did not detect differences for endpoints (abstinence duration estimated by percent of abstinent days, proportion of abstinent patients).
An inter-rater consistency of the three methodological subscores of r = 0.82 was found, and a principal components analysis detected a common first axis summarizing 78% of the variance. The factor score on the first components was highly correlated with the mean of items (r = 0.92), justifying the sum score of internal validity score, external validity score and statistical validity score as an overall methodological quality score.
Insomnia prevalence
The proportion of patients with high values for insomnia (score≥2) at baseline was 59.8% (95% CI 58.1-61.4). By using logistic regression, four risk factors were significantly identified (Table 2) : psychiatric history (0 = no, 1 = moderate, 2 = severe) with an odds ratio (OR) of 2.04 per level (1.77-2.34; P < 0.001); the Clinical Global Impression of the severity of baseline addiction (OR = 1.24 per level (1.15-1.33; P < 0.001); living alone compared with living with partner (OR = 1.21, 1.03-1.38; P = 0.019); finally, GGT values (ratio on upper limit of normal) (OR = 1.04 per unit, 1.01-1.07; P < 0.001). No other variable was identified as risk factor. After adjusting for these factors, the prevalence of insomnia did not differ among studies.
Treatment effect on insomnia improvement
Among all the candidate baseline predictors through the stepwise exploratory strategy, only baseline SSI was considered as the essential covariate. The main two-level mixed model limited to SSI b covariate provided evidence of a highly significant overall effect of acamprosate of −0.386 (−0.507 to −0.255; P < 0.001); this effect was observed with a variation of SD = 0.121 (0.044-0.381; P = 0.021) among studies. No interaction effect was found between baseline insomnia and treatment (maximum P = 0.477).
The mean change over baseline (SSI f −SSI b )/SSI b was −26.4% and −45.3% for placebo and acamprosate, respectively. The metaanalytical estimate provided a difference of −19% (−25.5 to −12.5; P < 0.001, forest plot, Fig. 2) .
By considering a patient as responding to therapy when the final SSI f ≤1 (validated minimum cut-off, Perney et al., 2015) , the overall observed responder rates were 39.2% and 51.2% within the placebo and acamprosate groups, respectively. Based on a random model, the relative benefit (benefit ratio acamprosate:placebo) was Br a:p = 1.33 (1.21-1.47, I 2 = 25.5%; P < 0.001) (Fig. 3) .
The proportion of abstainers at the end of the trial (no alcohol consumption during the 6-month follow-up) was 20.1% and 28.4% in the placebo and acamprosate groups, respectively (BR a:p = 1.43 (1.24-1.64; P < 0.001). For both endpoints, no publication bias was suspected from the funnel plot method or the linear fitting between the log odds ratio and its standard error (P = 0.671). Moreover, the coefficient of variation over the four missing data allocation techniques was 2.12%, providing evidence of very little variation depending on missing data allocation. [ -25.46 , -12.49 ] placebo (n) acamp (n) Favours placebo ⇒ 
Assessment of the mediation effect of abstinence on insomnia improvement
As acamprosate's exclusive effect is enhancing abstinence (Jonas et al., 2014) , the extent to which the beneficial effect observed on insomnia might be explained by the mediating effect of abstinence on insomnia relief: univariate mediation model (Preacher and Hayes, 2008) ( Table 3 ). The overall effect of acamprosate on the proportion of responders (SSI f ≤1) adjusted for baseline values was an increase of 11.6% (7.6-15.6). The estimated effect of acamprosate on percent of abstinent days was an increase of 9.3% (6.5-12.2), compared with placebo, whereas the direct effect of percent of abstinent days on responder proportion (for insomnia) was an increase of 69.6% (66.2-72.3). Thus, the indirect effect of treatment mediated by abstinence (estimated by percent of abstinent days) was 0.696*0.093 = 6.5%, and the mediating effect of percent of abstinent days was 6.5/ 11.6 = 55.7% of the total effect of acamprosate (bootstrapped 35.3-79.9). Therefore, the remaining unexplained effect of acamprosate was 44.3% (20.1-64.7).
DISCUSSION
Our results are based on an individual patient data meta-analysis, in which sleep disorders were evaluated using anxiety and depression questionnaires in taking advantage of our recent findings that a subset of Hamilton depression and Anxiety Scale provided a reliable and sensitive measurement of insomnia. Our estimate of overall prevalence of insomnia was 59.8% and was homogeneous irrespective of studies and countries. These results must be compared to those of studies that included alcoholic patients during acute withdrawal, i.e. suffering from a similar form of insomnia (Chakravorty et al., 2016) . In these studies, the prevalence of sleep disturbance ranged from 54% to 92% among males (Caetano et al., 1998; Steinig et al., 2011) and could reach 100% among females (Escobar-Cordoba et al., 2009) .
This sample constitutes a representative and large cohort of alcoholic patients based in several countries. To our knowledge, it is the largest cohort having assessed the prevalence of insomnia among alcoholic patients with 3508 enroled patients in 12 different studies.
During the 6-month follow-up, a decrease in insomnia was observed in both groups (placebo and acamprosate), with a significant advantage in favour of the acamprosate group. The study variability was low. These results confirmed on a large-scale prior publications on insomnia after alcohol withdrawal (Boeijinga et al., 2004; Staner et al., 2006; Perney et al., 2012) .
These data confirm preliminary results (Perney et al., 2012) on a larger sample size. The most important risk factors of insomnia at baseline are the history of psychiatric disease and depression or anxiety disorders, all known factors strongly associated with insomnia. These results also confirm prior publications, which showed that depressive (Foster and Peters, 1999; Brower et al., 2001 ) and anxiety symptoms (Baekeland et al., 1974) are predictors of insomnia in the subgroup of alcoholdependent patients. The impact of psychiatric problems on insomnia of alcoholic patients is probably underestimated since patients with the most severe psychiatric profile are systematically excluded from clinical trials evaluating drug effects. Moreover, as our insomnia evaluation was measured using anxiety and depression scales, these variables cannot be considered as independent in our study. Living alone is also an independent risk factor of insomnia persistence, confirming previous studies. Thus, studies in adults have shown that sleeping alone is associated with a feeling of less satisfied sleep (Troxel, 2010) , particularly a longer sleep latency (Chakravorty et al., 2013) . On the other hand, our study confirms the significant association between insomnia and increased serum GGT, previously shown to be associated with an increasing risk of insomnia (Perney et al., 2012) , probably as a marker of alcohol consumption. It may also have been an indicator of recent drinking and there is no knowledge specifically linking GGT with insomnia symptoms. Finally, a severe level of addiction constitutes another risk factor of insomnia, which confirms previous publications (Brower et al., 2001; Zhabenko et al., 2012; Hartwell et al., 2015) . Our result showing that abstinence reduces insomnia over a 6-month period does not enable any measurement of the extent of improvement in insomnia symptoms during withdrawal over time, particularly during the first weeks of abstinence.
On the other hand, these results are based on abstinence and not drinking reduction, our results showing an important positive effect of abstinence on insomnia reduction can only be considered in the context of continuous abstinence and not drinking reduction.
As shown in our main model, the severity of insomnia at baseline constitutes by far the most predictive covariate of insomnia at the end of treatment (the most severe at baseline, the most persistent at final time). We also failed to detect a significant interaction between treatment and baseline score of insomnia; thus, acamprosate effect remains constant irrespective of baseline insomnia severity.
The subset of the studies for which Hamilton scale was available (n = 3058, 12 studies) did not present differences compared with the whole acamprosate database (24 studies, 6543 patients). While these similarities do not fully exclude potential biases, the similarity of protocols, baseline conditions and the results did not provide any reason to suspect a difference. On the other hand, it is important to note that the selected studies had for aims the efficacy and the tolerance and that the included patients were psychiatrically stable and motivated for a treatment, which can constitute a selection bias. Moreover, the measurement criteria are insomnia symptoms and this does not include the burden resulting from insomnia, such as problems with social and interpersonal functioning that can lead to a miss-estimation of sleep disorders.
Furthermore, some limitations in the mediation models may be discussed. There are some possible limitations to our mediation model. The first is the lack of control for the baseline levels of the mediators, which should have been useful in ascertaining whether the support for the mediating effects is due to acamprosate or merely an artefact of baseline associations between drinking and insomnia. A second limitation is its univariate nature; a multilevel mediation model is recommended. This analysis was provided as a secondary endpoint and needs further development. The third limitation lies in possible problems in combining binary and categorical covariates, which could lead to bias in the indirect effect and proportion-mediated statistics.
The exclusive recognized effect of acamprosate was maintaining alcohol abstinence. Until now, no other treatment has shown significant results for both abstinence and sleep disorders in alcohol-dependent patients (Brower et al., 2008; Friedmann et al., 2008) . To which extent the beneficial effect of acamprosate in enhancing abstinence partly and totally explains insomnia relief was studied through a univariate mediation model (Fig. 3) . In this model, we provide evidence that reduced consumption partly explains improvement of insomnia with a proportion of 55%. Thus, an important residual effect (45%) of acamprosate remains to be identified. Only conjectures are possible, one of them being the intrinsic effect of acamprosate corresponding to the regulation of glutamatergic tone whose dysregulation after alcohol withdrawal is known to favour sleep disorders (Krystal et al., 2003) .
CONCLUSION
Insomnia is prevalent (60%) among alcohol-dependent patients, predictable by a few risk factors (psychiatric history, severe addiction, living alone and raised serum GGT). Acamprosate has a significant effect in reducing insomnia compared with placebo.
